Wang 2018b.

Methods	Study design: Randomised clinical trial Study duration: January 2013 to January 2017 Duration of follow‐up: 1 year Setting: Hospital
Participants	Inclusion criteria: Diagnosed as HCC by biopsy and images; with liver function of Child‐Pugh Class A or B; adequate haematopoietic function; tumour number ≤ 3; no extrahepatic metastasis Exclusion criteria: With hepatic arterio‐venous fistula; abnormal renal or cardiac function Age (mean ± SD, range): TACE + RFA: 43.02 ± 7.14 years, 41‐63 years; TACE: 40.48 ± 7.26 years, 37‐59 years Male (n/total): TACE + RFA: 14/27; TACE alone: 15/27 Child‐Pugh Class (patients): Class A: TACE + RFA: 18; TACE: 15 Class B: TACE + RFA: 9; TACE: 12
Interventions	TACE + RFA group (n = 27): TACE: Chemotherapeutic drugs: oxaliplatin and 5‐fluorouracil RFA: The interval between TACE and RFA was 1 week. TACE group (n = 27): Chemotherapeutic drugs: oxaliplatin and 5‐fluorouracil
Outcomes	Serum level of AFP Liver function Tumour response, classified as complete response, partial response, stable disease, and progression 1‐year survival, recurrence, and metastasis rate
Notes	Country of study: China Source of funding: None There was insufficient information available to satisfactorily determine the method of randomisation and the study data could not be verified. We have attempted to contact the study authors for more information, but so far, we have not been successful in doing this.